Davita Inc. Stock
Davita Inc. Stock
Davita Inc. shows a slight decrease today, losing -€0.600 (-0.390%) compared to yesterday.
Our community is currently high on Davita Inc. with 4 Buy predictions and 1 Sell predictions.
On the other hand, the target price of 119 € is below the current price of 151.95 € for Davita Inc., so the potential is actually -21.68%.
Our community identified positive and negative aspects for Davita Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Davita Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Davita Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Davita Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Davita Inc. | -0.390% | -0.388% | -25.724% | 34.646% | 59.581% | 64.740% | 37.718% |
| Chemed Corp. | -1.310% | -3.448% | 5.164% | 18.519% | 23.077% | - | - |
| Molina Healthcare | -1.900% | 4.421% | -10.685% | 21.345% | 20.514% | -39.139% | -18.617% |
| Teladoc Health Inc | 0.540% | -5.122% | -32.095% | -12.812% | -5.267% | -73.675% | -95.261% |
Comments
DaVita (DVA) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for DVA provided by MarketBeat
DaVita (DVA) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for DVA provided by MarketBeat
DaVita (DVA) was upgraded by Zacks Research from "hold" to "strong-buy".
Show more
Ratings data for DVA provided by MarketBeat